TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

Blockchain, nanomedicine, and 3D printing signal a growing emphasis on improving healthcare delivery through innovative ...

Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.

Imagine a humanoid robot with not two, but six arms, as if it had dropped straight out of Indian mythology. This is the MIRO ...

After years of research, scientists in China have created a bone-free fish, which has been named 'Zhongke No. 6'. The new ...

Corynebacterium glutamicum S9114, a superior strain widely used in glutamic acid industrial production through traditional mutagenesis screening, is ...

As the year draws to a close, we take a look at some of the biggest science stories of the year, and why they matter.

In one of the rockiest years yet for science, Philadelphia-area researchers still managed to celebrate many wins. Here are five of them.

Researchers call the development a "game-changer" for aquaculture, signalling how precision genetics may increasingly ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $53.19, marking a -1.45% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. At ...